Enhancing the quality of antibodies to HIV-1 envelope by GagPol-specific Th cells

Journal of Immunology

Volumn 195, Issue 10, 2015, Pages 4861-4872

  Bonsmann, Michael Storcksdieck Genannt ^a   Niezold, Thomas ^a   Temchura, Vladimir ^a,b   Pissani, Franco ^c   Ehrhardt, Katrin ^d   Brown, Eric P ^e   Osei Owusu, Nana Yaw ^e   Hannaman, Drew ^f   Hengel, Hartmut ^d   Ackerman, Margaret E ^e   Streeck, Hendrik ^c   Nabi, Ghulam ^a   Tenbusch, Matthias ^a   Überla, Klaus ^a,b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c US Military HIV Research Program   (United States)

^d UNIVERSITY OF FREIBURG   (Germany)

^e DARTMOUTH COLLEGE   (United States)

^f Ichor Medical Systems Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; GAG PROTEIN; GLYCAN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLASMID DNA; POL PROTEIN; VIRUS ENVELOPE PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS ENVELOPE; VIRUS LIKE AGENT; ANIMAL; BAGG ALBINO MOUSE; CLINICAL TRIAL; FEMALE; HEK293 CELL LINE; HELPER CELL; IMMUNOLOGY; MALE; TUMOR CELL LINE;

AIDS VACCINES; ANIMALS; CELL LINE, TUMOR; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HEK293 CELLS; HIV ANTIBODIES; HIV-1; HUMANS; MALE; MICE; MICE, INBRED BALB C; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84958677647     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1501377     Document Type: Article

References (81)

1. Plotkin, S. A. 2008. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 47: 401-409.
2. Yates, N. L., H. X. Liao, Y. Fong, A. deCamp, N. A. Vandergrift,W. T. Williams, S. M. Alam, G. Ferrari, Z. Y. Yang, K. E. Seaton, et al. 2014. Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination. Sci. Trans. Med. 6: 228ra39.
3. Chung, A. W., M. Ghebremichael, H. Robinson, E. Brown, I. Choi, S. Lane, A. S. Dugast, M. K. Schoen, M. Rolland, T. J. Suscovich, et al. 2014. Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines. Sci. Trans. Med. 6: 228ra38.
4. Haynes, B. F., P. B. Gilbert, M. J. McElrath, S. Zolla-Pazner, G. D. Tomaras, S. M. Alam, D. T. Evans, D. C. Montefiori, C. Karnasuta, R. Sutthent, et al. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366: 1275-1286.
5. Vidarsson, G., G. Dekkers, and T. Rispens. 2014. IgG subclasses and allotypes: from structure to effector functions. Front. Immunol. 5: 520.
6. Nimmerjahn, F., and J. V. Ravetch. 2008. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8: 34-47.
7. Hessell, A. J., L. Hangartner, M. Hunter, C. E. G. Havenith, F. J. Beurskens, J. M. Bakker, C. M. S. Lanigan, G. Landucci, D. N. Forthal, P. W. H. I. Parren, et al. 2007. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449: 101-104.
8. Bournazos, S., F. Klein, J. Pietzsch, M. S. Seaman, M. C. Nussenzweig, and J. V. Ravetch. 2014. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158: 1243-1253.
9. Snapper, C. M., and W. E. Paul. 1987. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 236: 944-947.
10. Murray, J. S. 1998. How the MHC selects Th1/Th2 immunity. Immunol. Today 19: 157-163.
11. Abdoli, R., and N. Najafian. 2014. T Helper Cells Fate Mapping by Costimulatory Molecules and its Functions in Allograft Rejection and Tolerance. Int. J. Organ Transplant. Med. 5: 97-110.
12. Iwasaki, A., and R. Medzhitov. 2004. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5: 987-995.
13. Geijtenbeek, T. B. H., and S. I. Gringhuis. 2009. Signalling through C-type lectin receptors: shaping immune responses. Nat. Rev. Immunol. 9: 465-479.
14. Pulendran, B., and R. Ahmed. 2011. Immunological mechanisms of vaccination. Nat. Immunol. 12: 509-517.
15. Jankovic, D., P. Caspar, M. Zweig, M. Garcia-Moll, S. D. Showalter, F. R. Vogel, and A. Sher. 1997. Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120. J. Immunol. 159: 2409-2417.
16. Daly, L. M., P. A. Johnson, G. Donnelly, C. Nicolson, J. Robertson, and K. H. G. Mills. 2005. Innate IL-10 promotes the induction of Th2 responses with plasmid DNA expressing HIV gp120. Vaccine 23: 963-974.
17. Banerjee, K., S. Andjelic, P. J. Klasse, Y. Kang, R. W. Sanders, E. Michael, R. J. Durso, T. J. Ketas, W. C. Olson, and J. P. Moore. 2009. Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo. Virology 389: 108-121.
18. Baumgartner, C. K., and L. P. Malherbe. 2010. Regulation of CD4 T-cell receptor diversity by vaccine adjuvants. Immunology 130: 16-22.
19. Coffman, R. L., A. Sher, and R. A. Seder. 2010. Vaccine adjuvants: putting innate immunity to work. Immunity 33: 492-503.
20. Visciano, M. L., M. Tuen, M. K. Gorny, and C. E. Hioe. 2008. In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120. Virology 372: 409-420.
21. Russell, S. M., and F. Y. Liew. 1979. T cells primed by influenza virion internal components can cooperate in the antibody response to haemagglutinin. Nature 280: 147-148.
22. Scherle, P. A., and W. Gerhard. 1986. Functional analysis of influenza-specific helper T cell clones in vivo. T cells specific for internal viral proteins provide cognate help for B cell responses to hemagglutinin. J. Exp. Med. 164: 1114-1128.
23. Milich, D. R., A. McLachlan, G. B. Thornton, and J. L. Hughes. 1987. Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site. Nature 329: 547-549.
24. Sette, A., M. Moutaftsi, J. Moyron-Quiroz, M. M. McCausland, D. H. Davies, R. J. Johnston, B. Peters, M. Rafii-El-Idrissi Benhnia, J. Hoffmann, H.-P. Su, et al. 2008. Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities. Immunity 28: 847-858.
25. Nabi, G., M. S. Genannt Bonsmann, M. Tenbusch, O. Gardt, D. H. Barouch, V. Temchura, and K. Uberla. 2013. GagPol-specific CD4+ T-cells increase the antibody response to Env by intrastructural help. Retrovirology 10: 117.
26. Wagner, R., M. Graf, K. Bieler, H. Wolf, T. Grunwald, P. Foley, and K. Uberla. 2000. Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors. Hum. Gene Ther. 11: 2403-2413.
27. Kothe, D. L., J. M. Decker, Y. Li, Z. Weng, F. Bibollet-Ruche, K. P. Zammit, M. G. Salazar, Y. Chen, J. F. Salazar-Gonzalez, Z. Moldoveanu, et al. 2007. Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology 360: 218-234.
28. Yang, X., J. Lee, E. M. Mahony, P. D. Kwong, R. Wyatt, and J. Sodroski. 2002. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J. Virol. 76: 4634-4642.
29. Kamdem Toukam, D., M. Tenbusch, A. Stang, V. Temchura, M. Storcksdieck Genannt Bonsmann, B. Grewe, S. Koch, A. Meyerhans, G. Nchinda, L. Kaptue, and K. Uberla. 2012. Targeting antibody responses to the membrane proximal external region of the envelope glycoprotein of human immunodeficiency virus. PLoS One 7: e38068.
30. Eller, M. A., B. M. Slike, J. H. Cox, E. Lesho, Z. Wang, J. R. Currier, J. M. Darden, V. R. Polonis, M. T. Vahey, S. Peel, et al. 2011. A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells. PLoS One 6: e24254.
31. Liao, H.-X., L. L. Sutherland, S.-M. Xia, M. E. Brock, R. M. Scearce, S. Vanleeuwen, S. M. Alam, M. McAdams, E. A. Weaver, Z. Camacho, et al. 2006. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 353: 268-282.
32. Melmer, M., T. Stangler, M. Schiefermeier, W. Brunner, H. Toll, A. Rupprechter, W. Lindner, and A. Premstaller. 2010. HILIC analysis of fluorescence-labeled Nglycans from recombinant biopharmaceuticals. Anal. Bioanal. Chem. 398: 905-914.
33. Ruhaak, L. R., C. Huhn, W.-J. Waterreus, A. R. de Boer, C. Neusüss, C. H. Hokke, A. M. Deelder, and M. Wuhrer. 2008. Hydrophilic interaction chromatography-based high-throughput sample preparation method for N-glycan analysis from total human plasma glycoproteins. Anal. Chem. 80: 6119-6126.
34. Corrales-Aguilar, E., M. Trilling, H. Reinhard, E. Mercé-Maldonado, M.Widera, H. Schaal, A. Zimmermann, O. Mandelboim, and H. Hengel. 2013. A novel assay for detecting virus-specific antibodies triggering activation of Fcg receptors. J. Immunol. Methods 387: 21-35.
35. Kong, L., N. C. Sheppard, G. B. E. Stewart-Jones, C. L. Robson, H. Chen, X. Xu, G. Krashias, C. Bonomelli, C. N. Scanlan, P. D. Kwong, et al. 2010. Expressionsystem-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicity. J. Mol. Biol. 403: 131-147.
36. Grnevik, E., I. Mathiesen, and T. Lemo. 2005. Early events of electroporationmediated intramuscular DNA vaccination potentiate Th1-directed immune responses. J. Gene Med. 7: 1246-1254.
37. Mestas, J., and C. C. W. Hughes. 2004. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172: 2731-2738.
38. Flynn, N. M., D. N. Forthal, C. D. Harro, F. N. Judson, K. H. Mayer, and M. F. Para, rgp120 HIV Vaccine Study Group. 2005. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191: 654-665.
39. Pitisuttithum, P., P. Gilbert, M. Gurwith, W. Heyward, M. Martin, F. van Griensven, D. Hu, J. W. Tappero, and K. Choopanya, Bangkok Vaccine Evaluation Group. 2006. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194: 1661-1671.
40. Rerks-Ngarm, S., P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu, R. Paris, N. Premsri, C. Namwat, M. de Souza, E. Adams, et al; MOPH-TAVEG Investigators. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361: 2209-2220.
41. Nimmerjahn, F., A. Lux, H. Albert, M. Woigk, C. Lehmann, D. Dudziak, P. Smith, and J. V. Ravetch. 2010. FcgRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc. Natl. Acad. Sci. USA 107: 19396-19401.
42. Geall, A. J., A. Verma, G. R. Otten, C. A. Shaw, A. Hekele, K. Banerjee, Y. Cu, C. W. Beard, L. A. Brito, T. Krucker, et al. 2012. Nonviral delivery of selfamplifying RNA vaccines. Proc. Natl. Acad. Sci. USA 109: 14604-14609.
43. Stab, V., S. Nitsche, T. Niezold, M. Storcksdieck Genannt Bonsmann, A. Wiechers, B. Tippler, D. Hannaman, C. Ehrhardt, K. Uberla, T. Grunwald, and M. Tenbusch. 2013. Protective efficacy and immunogenicity of a combinatory DNA vaccine against Influenza A Virus and the Respiratory Syncytial Virus. PLoS One 8: e72217.
44. Markine-Goriaynoff, D., and J.-P. Coutelier. 2002. Increased efficacy of the immunoglobulin G2a subclass in antibody-mediated protection against lactate dehydrogenase-elevating virus-induced polioencephalomyelitis revealed with switch mutants. J. Virol. 76: 432-435.
45. Ishizaka, S. T., P. Piacente, J. Silva, and E. M. Mishkin. 1995. IgG subtype is correlated with efficiency of passive protection and effector function of anti-herpes simplex virus glycoprotein D monoclonal antibodies. J. Infect. Dis. 172: 1108-1111.
46. Schlesinger, J. J., M. Foltzer, and S. Chapman. 1993. The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice. Virology 192: 132-141.
47. DiLillo, D. J., G. S. Tan, P. Palese, and J. V. Ravetch. 2014. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgR interactions for protection against influenza virus in vivo. Nat. Med. 20: 143-151.
48. Ishizaka, A., Y. Sakiyama, M. Nakanishi, K. Tomizawa, E. Oshika, K. Kojima, Y. Taguchi, E. Kandil, and S. Matsumoto. 1990. The inductive effect of interleukin-4 on IgG4 and IgE synthesis in human peripheral blood lymphocytes. Clin. Exp. Immunol. 79: 392-396.
49. Punnonen, J., G. Aversa, B. G. Cocks, A. N. McKenzie, S. Menon, G. Zurawski, R. de Waal Malefyt, and J. E. de Vries. 1993. Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc. Natl. Acad. Sci. USA 90: 3730-3734.
50. Kimata, H., M. Fujimoto, and K. Furusho. 1995. Involvement of interleukin (IL)-13, but not IL-4, in spontaneous IgE and IgG4 production in nephrotic syndrome. Eur. J. Immunol. 25: 1497-1501.
51. Jeannin, P., S. Lecoanet, Y. Delneste, J. F. Gauchat, and J. Y. Bonnefoy. 1998. IgE versus IgG4 production can be differentially regulated by IL-10. J. Immunol. 160: 3555-3561.
52. Karagiannis, P., A. E. Gilbert, D. H. Josephs, N. Ali, T. Dodev, L. Saul, I. Correa, L. Roberts, E. Beddowes, A. Koers, et al. 2013. IgG4 subclass antibodies impair antitumor immunity in melanoma. J. Clin. Invest. 123: 1457-1474.
53. Elgueta, R., M. J. Benson, V. C. de Vries, A. Wasiuk, Y. Guo, and R. J. Noelle. 2009. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev. 229: 152-172.
54. Erickson, L. D., B. G. Durell, L. A. Vogel, B. P. O'Connor, M. Cascalho, T. Yasui, H. Kikutani, and R. J. Noelle. 2002. Short-circuiting long-lived humoral immunity by the heightened engagement of CD40. J. Clin. Invest. 109: 613-620.
55. Kishi, Y., Y. Aiba, T. Higuchi, K. Furukawa, T. Tokuhisa, T. Takemori, and T. Tsubata. 2010. Augmented antibody response with premature germinal center regression in CD40L transgenic mice. J. Immunol. 185: 211-219.
56. Bonsignori, M., M. A. Moody, R. J. Parks, T. M. Holl, G. Kelsoe, C. B. Hicks, N. Vandergrift, G. D. Tomaras, and B. F. Haynes. 2009. HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. J. Immunol. 183: 2708-2717.
57. Klasse, P. J., R. W. Sanders, A. Cerutti, and J. P. Moore. 2012. How can HIVtype-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? AIDS Res. Hum. Retroviruses 28: 1-15.
58. Lewis, G. K., A. L. DeVico, and R. C. Gallo. 2014. Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development. Proc. Natl. Acad. Sci. USA 111: 15614-15621.
59. Fouts, T. R., K. Bagley, I. J. Prado, K. L. Bobb, J. A. Schwartz, R. Xu, R. J. Zagursky, M. A. Egan, J. H. Eldridge, C. C. LaBranche, et al. 2015. Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection. [Published erratum appears in Proc. Natl. Acad. Sci. USA 112: E2413.] Proc. Natl. Acad. Sci. USA 112: E992-E999.
60. Tenbusch, M., R. Ignatius, V. Temchura, G. Nabi, B. Tippler, G. Stewart-Jones, A. M. Salazar, ü. Sauermann, C. Stahl-Hennig, and K. Uberla. 2012. Risk of immunodeficiency virus infection may increase with vaccine-induced immune response. J. Virol. 86: 10533-10539.
61. Uberla, K. 2008. HIV vaccine development in the aftermath of the STEP study: re-focus on occult HIV infection? PLoS Pathog. 4: e1000114.
62. Wang, J., C. I. A. Balog, K. Stavenhagen, C. A. M. Koeleman, H. U. Scherer, M. H. J. Selman, A. M. Deelder, T. W. J. Huizinga, R. E. M. Toes, and M. Wuhrer. 2011. Fc-glycosylation of IgG1 is modulated by B-cell stimuli. Mol. Cell Proteomics 10: M110.004655.
63. Shields, R. L., J. Lai, R. Keck, L. Y. O'Connell, K. Hong, Y. G. Meng, S. H. A. Weikert, and L. G. Presta. 2002. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277: 26733-26740.
64. Shinkawa, T., K. Nakamura, N. Yamane, E. Shoji-Hosaka, Y. Kanda, M. Sakurada, K. Uchida, H. Anazawa, M. Satoh, M. Yamasaki, et al. 2003. The absence of fucose but not the presence of galactose or bisecting Nacetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278: 3466-3473.
65. Forthal, D. N., J. S. Gach, G. Landucci, J. Jez, R. Strasser, R. Kunert, and H. Steinkellner. 2010. Fc-glycosylation influences Fcg receptor binding and cellmediated anti-HIV activity of monoclonal antibody 2G12. J. Immunol. 185: 6876-6882.
66. Zeitlin, L., J. Pettitt, C. Scully, N. Bohorova, D. Kim, M. Pauly, A. Hiatt, L. Ngo, H. Steinkellner, K. J. Whaley, and G. G. Olinger. 2011. Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc. Natl. Acad. Sci. USA 108: 20690-20694.
67. Umaña, P., J. Jean-Mairet, R. Moudry, H. Amstutz, and J. E. Bailey. 1999. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 17: 176-180.
68. Davies, J., L. Jiang, L. Z. Pan, M. J. LaBarre, D. Anderson, and M. Reff. 2001. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol. Bioeng. 74: 288-294.
69. Kaneko, Y., F. Nimmerjahn, and J. V. Ravetch. 2006. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313: 670-673.
70. Oefner, C. M., A. Winkler, C. Hess, A. K. Lorenz, V. Holecska, M. Huxdorf, T. Schommartz, D. Petzold, J. Bitterling, A.-L. Schoen, et al. 2012. Tolerance induction with T cell-dependent protein antigens induces regulatory sialylated IgGs. J. Allergy Clin. Immunol. 129: 1647-1655.e13.
71. Hess, C., A. Winkler, A. K. Lorenz, V. Holecska, V. Blanchard, S. Eiglmeier, A.-L. Schoen, J. Bitterling, A. D. Stoehr, D. Petzold, et al. 2013. T cellindependent B cell activation induces immunosuppressive sialylated IgG antibodies. J. Clin. Invest. 123: 3788-3796.
72. Scallon, B. J., S. H. Tam, S. G. McCarthy, A. N. Cai, and T. S. Raju. 2007. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol. Immunol. 44: 1524-1534.
73. Nimmerjahn, F., and J. V. Ravetch. 2005. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310: 1510-1512.
74. Nimmerjahn, F., P. Bruhns, K. Horiuchi, and J. V. Ravetch. 2005. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23: 41-51.
75. Bruhns, P. 2012. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119: 5640-5649.
76. Tomaras, G. D., G. Ferrari, X. Shen, S. M. Alam, H.-X. Liao, J. Pollara, M. Bonsignori, M. A. Moody, Y. Fong, X. Chen, et al. 2013. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc. Natl. Acad. Sci. USA 110: 9019-9024.
77. Bonsignori, M., J. Pollara, M. A. Moody, M. D. Alpert, X. Chen, K.-K. Hwang, P. B. Gilbert, Y. Huang, T. C. Gurley, D. M. Kozink, et al. 2012. Antibodydependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J. Virol. 86: 11521-11532.
78. van Gils, M. J., and R. W. Sanders. 2013. Broadly neutralizing antibodies against HIV-1: templates for a vaccine. Virology 435: 46-56.
79. Liao, H.-X., R. Lynch, T. Zhou, F. Gao, S. M. Alam, S. D. Boyd, A. Z. Fire, K. M. Roskin, C. A. Schramm, Z. Zhang, et al. 2013. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496: 469-476.
80. Wu, X., T. Zhou, J. Zhu, B. Zhang, I. Georgiev, C. Wang, X. Chen, N. S. Longo, M. Louder, K. McKee, et al; NISC Comparative Sequencing Program. 2011. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333: 1593-1602.
81. Haynes, B. F., M. A. Moody, H.-X. Liao, L. Verkoczy, and G. D. Tomaras. 2011. B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. Trends Mol. Med. 17: 108-116.